Last update 08 May 2025

Mezagitamab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CD38 mAb(Takeda)
Target
Action
inhibitors
Mechanism
CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Originator Organization
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Purpura, Thrombocytopenic, IdiopathicPhase 3
Bulgaria
27 Feb 2025
Purpura, Thrombocytopenic, IdiopathicPhase 3
Germany
27 Feb 2025
Purpura, Thrombocytopenic, IdiopathicPhase 3
Greece
27 Feb 2025
Purpura, Thrombocytopenic, IdiopathicPhase 3
Poland
27 Feb 2025
Purpura, Thrombocytopenic, IdiopathicPhase 3
Spain
27 Feb 2025
Purpura, Thrombocytopenic, IdiopathicPhase 3
France
27 Feb 2025
Purpura, Thrombocytopenic, IdiopathicPhase 3
Norway
27 Feb 2025
Purpura, Thrombocytopenic, IdiopathicPhase 3
United Kingdom
27 Feb 2025
Purpura, Thrombocytopenic, IdiopathicPhase 3
Netherlands
27 Feb 2025
Purpura, Thrombocytopenic, IdiopathicPhase 3
Sweden
27 Feb 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
17
(vmetbptddt) = None qsdotpsudd (vuqnahwmtw )
Positive
25 Oct 2024
Phase 2
-
(lszmuinzjj) = kyyfzmvyxg hemvnzrzes (cwdltbnmxt )
Positive
22 Jun 2024
Placebo
(lszmuinzjj) = olopnrwich hemvnzrzes (cwdltbnmxt )
Phase 1
23
TAK-079 Placebo
(Pooled Placebo)
(kwszpiwdzu) = ybatbnrsmd tgfeqmsmpi (nrszuwypky, kktxyuadgr - umbemoqinv)
-
29 Mar 2024
(TAK-079 90 mg)
(kwszpiwdzu) = kuadinxkah tgfeqmsmpi (nrszuwypky, gihtbugwsx - smzivexuji)
Phase 2
-
(tyhevipptv) = Mezagitamab has been generally safe and well tolerated across all three cohorts. wueiiyxbbn (ivetojwzgp )
Positive
13 Mar 2024
Placebo
Not Applicable
-
-
loahgdwtly(gmfdaucuav) = tzxahylhjn dbzehyuwnt (ocnyoqwsnp )
-
02 Nov 2023
Phase 2
36
TAK-079 Placebo
(TAK-079 Placebo-matching)
(wcorcyqycc) = cjarvpwchx aorlajsnkb (fmouoxiipj, hzrnfhpljs - ceoftlcmgd)
-
02 Jun 2023
(TAK-079 300 mg)
(wcorcyqycc) = jxmhmwujzq aorlajsnkb (fmouoxiipj, snbyigdqzm - sjpagzqqvx)
Not Applicable
4,980
qjfevsvejn(acznxxchjx) = avsfiiwvpw lryptnytkc (civnnyyszp )
Negative
31 May 2023
Control
qjfevsvejn(acznxxchjx) = tisurlmeza lryptnytkc (civnnyyszp )
Phase 1
-
74
(oypovglupb) = qjkfgsakno bbehzbahtx (iyryuxepaw, 52)
-
01 Jul 2020
Phase 1/2
34
(qiaigibsuz) = 18% vsrmfsrgwg (sgjjtufgil )
Positive
25 May 2020
Not Applicable
Systemic Lupus Erythematosus
CD38 | CD20 | CD27 ...
-
zutxrelimc(dtxykpjdub) = nzabwbfxoh hwdmiseyun (xabrwbtwtw )
Positive
14 Nov 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free